Literature DB >> 1409365

Stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (lobaplatin; D19466) in intravenous solutions.

H J Guchelaar1, D R Uges, P Aulenbacher, E G de Vries, N H Mulder.   

Abstract

The chemical stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (D19466) in infusion media was studied in an accelerated stability testing experiment with a selective HPLC-UV method. Variables were time, temperature, light, concentration, and infusion mixture. Mean reaction rate constants of decomposition were, respectively, 0.9555 *10(-2), 2.127 *10(-2), and 4.221 *10(-2) hr-1 at 37, 56, and 66 degrees C at a concentration of 200 mg/L in normal saline. From the Arrhenius equation, shelf lives (5% loss) at 4, 22, 37, and 121 degrees C were, respectively, calculated to be 41.6, 13.2, 5.7, and 0.15 hr. Mean reaction rate constant in 5% dextrose was 3.106 *10(-2) hr-1 (200 mg/L; 56 degrees C) and differed from that in normal saline (P less than 0.005). Mean reaction rate constant in Ringer lactate was 2.084 *10(-2) hr-1 (200 mg/L; 56 degrees C) (P greater than 0.05). There was no influence of normal daylight on the rate of decomposition. It is recommended to prepare D19466 infusions in normal saline. Chemical stability is then maximal 12 hr at room temperature or 24 hr at 4 degrees C. No protection against normal daylight is required. Sterilization by heat is not possible.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1409365     DOI: 10.1023/a:1015815908347

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

Review 1.  Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.

Authors:  P A Andrews; S B Howell
Journal:  Cancer Cells       Date:  1990-02

2.  Cis-platin stability in aqueous parenteral vehicles.

Authors:  A A Hincal; D F Long; A J Repta
Journal:  J Parenter Drug Assoc       Date:  1979 May-Jun

3.  Protein binding of five platinum compounds. Comparison of two ultrafiltration systems.

Authors:  W J van der Vijgh; I Klein
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  D-19466, a new cyclobutane-platinum complex with antitumor activity.

Authors:  R Voegeli; W Schumacher; J Engel; J Respondek; P Hilgard
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

5.  Stability of cisplatin in aqueous solution.

Authors:  R F Greene; D C Chatterji; P K Hiranaka; J F Gallelli
Journal:  Am J Hosp Pharm       Date:  1979-01

Review 6.  Drugs five years later. Cisplatin.

Authors:  P J Loehrer; L H Einhorn
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

7.  Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.

Authors:  Y W Cheung; J C Cradock; B R Vishnuvajjala; K P Flora
Journal:  Am J Hosp Pharm       Date:  1987-01

8.  Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin.

Authors:  P T Daley-Yates; D C McBrien
Journal:  Biochem Pharmacol       Date:  1984-10-01       Impact factor: 5.858

9.  Determination of ethylenediamineplatinum(II) malonate in infusion fluids, human plasma and urine by high-performance liquid chromatography.

Authors:  W J van der Vijgh; F Elferink; G J Postma; J B Vermorken; H M Pinedo
Journal:  J Chromatogr       Date:  1984-10-12

10.  A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

Authors:  J A Gietema; E G de Vries; D T Sleijfer; P H Willemse; H J Guchelaar; D R Uges; P Aulenbacher; R Voegeli; N H Mulder
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

View more
  2 in total

1.  Distribution of platinum group elements (Pt, Pd, Rh) in environmental and clinical matrices: Composition, analytical techniques and scientific outlook: Status report.

Authors:  T Hees; B Wenclawiak; S Lustig; P Schramel; M Schwarzer; M Schuster; D Verstraete; R Dams; E Helmers
Journal:  Environ Sci Pollut Res Int       Date:  1998       Impact factor: 4.223

2.  Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.

Authors:  J A Gietema; G J Veldhuis; H J Guchelaar; P H Willemse; D R Uges; A Cats; H Boonstra; W T van der Graaf; D T Sleijfer; E G de Vries
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.